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1. Introduction 
Renal cell carcinoma (RCC) is the third leading cause of death among urological tumours, 
annually afflicts about 150, 000 people globally and causes nearly 78, 000 deaths (Jemal et al., 
2008; Zbar et al., 2003). RCC is an epithelial tumour consisting of several different 
histological subtypes of which clear cell RCC is the prototypical. Traditionally treatment has 
been via surgery and immunotherapy. Surgical resection is appropriate for some patient 
cohorts including those with isolated metastases. However, recurrence is common even 
when the primary and metastatic sites have been aggressively resected (Couillard & deVere 
White, 1993). RCC is highly unresponsive to standard chemotherapy and the use of cytokine 
therapy with interleukin (IL)-2 or interferon (IFN)-ǂ is associated with low rates of response 
and high rates of toxicity (Oudard et al., 2007). Thus, development of new therapies 
continues to be crucial to improve outcomes in patients with RCC. 
The increased understanding of the molecular structure and aberrant activity of signalling 
pathways  in RCC has lead to a flurry of research activity in the arena of targeted therapies 
namely anti-angiogenic vascular endothelial growth factor (VEGF) and the mammalian 
target of rapamycin (mTOR), both of which are involved in the pathogenesis of RCC 
(Mulders, 2009). These advancements in an obvious therapeutic gap have significantly 
improved the progression free survival (PFS) of patients with RCC. Despite the explosion in 
drug development during the past five years, however, PFS for patients with metastatic 
RCC (mRCC) still remains poor as none of the current targeted therapies possess the 
capacity to induce remission. In addition these drugs provide dose-limiting toxic side effects 
and so we are still faced with a considerable task in developing newer safer therapeutics for 
use as either first line agents or in combination with existing ones.  
2. Targeted therapy for RCC 
As the understanding of the molecular biology underlying RCC has increased, various 
components of growth and angiogenic signal transduction pathways have been identified as 
rational targets for therapeutic intervention in the treatment of patients with RCC and 
mRCC. The VEGF/VEGF receptor (VEGFR) pathway is one such target. VEGF expression is 
induced under hypoxic conditions triggering several mechanisms that promote 
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angiogenesis (Ellis & Hicklin, 2008). Members of the VEGF family namely VEGF-A, -B, -C 
and –D regulate angiogenesis through binding to the related family of receptor tyrosine 
kinases (RTKs): VEGF receptors (VEGFR)-1, -2 and -3.  The VEGFR consists of an 
extracellular ligand binding site, a transmembrane ǂ-helical domain and an intracellular 
protein-tyrosine kinase region. Once activated, phosphorylated tyrosine residues on these 
receptor kinases provide high-affinity binding sites for components of the Raf/MEK/ERK 
(MAP Kinase) and PI3K/AKT signalling pathways which mediate cell growth and 
angiogenesis. Inhibition of the pathway involving VEGF-A activation of VEGFR-2 has 
undergone the most extensive investigation in recent years. This pathway mediates the 
formation and preservation of the blood vessel network which is vital for tumour cell 
survival and proliferation (Casanovas et al., 2005). In RCC, VEGF is also a powerful tumour 
growth factor. RCCs over-express the different VEGFRs and also produce as paracrine and 
autocrine growth factors, large amounts of VEGF (Qian et al., 2009). In tumours the VEGF 
isoforms –C and –D have been shown to activate the VEGFR3 receptor and to initiate the 
development and maintenance of a lymphatic system (He et al., 2005). Targeting this process 
in cancer treatment is now in the early stages of development. Presently, different 
therapeutic avenues exist for inhibiting the activation of receptor tyrosine kinases (RTKs). 
Monoclonal antibodies (mAbs) against growth factor ligands, or antibody fragments against 
RTK ligand-binding domain, can prevent binding of growth factors, thus attenuating RTK 
activity. Alternatively, the protein kinase can be targeted. Drugs that bind reversibly to the 
ATP-binding site within the kinase domain or to a small pocket that is immediately adjacent 
to the ATP-binding site are used to block the enzymatic activity of the kinase. Due to 
similarities within the amino acid structure of the kinase domain, ATP-competitive 
inhibitors can have cross reactivity with other structurally related kinases.   
2.1 VEGF- antibody therapy/ligand competitors 
2.1.1 Bevacizumab 
Bevacizumab is an i.v. administered humanized monoclonal IgG1 antibody that targets and 
neutralises all major isoforms of circulating VEGF (Presta et al., 1997). By binding with high 
affinity to VEGF, bevacizumab inhibits its interaction with tyrosine kinase receptors thereby 
preventing the initiation of an angiogenic signal (Figure 1). This weakens existing 
microvasculature and production of new vasculature is inhibited. The loss of vascularisation 
eventually leads to tumour cell death (Jain, 2005). 
Bevacizumab is used in the treatment of a wide range of cancer types including RCC, colon, 
brain and lung cancers. It was approved in 2009 for the first-line treatment of patients with 
advanced RCC or mRCC in combination with IFN-ǂ. FDA approval came as a result of the 
phase III AVOREN trial. RCC patients following previous nephrectomy were randomized to 
receive either bevacizumab plus IFN-ǂ or placebo plus IFN-ǂ (Escudier et al., 2007a). The 
addition of bevacizumab to IFN-ǂ significantly improved both the overall response rate 
(ORR) (30.6 vs. 12.4%, P<0.0001) and PFS (10.2 vs. 5.4 months). Subgroup analysis, however, 
indicated that the advantage in PFS related only to favourable and intermediate risk patients 
and not to the poor risk group. The final overall survival (OS) results reported no significant 
difference between the bevacizumab and control groups (23.3 vs. 21.3 months). However, 
these findings may have been influenced by the fact that 63% of patients in the placebo plus 
IFN-ǂ group and 55% of patients in the bevacizumab plus IFN-ǂ group received second-line 
therapy with other agents (Escudier et al., 2010). 
www.intechopen.com
Exploitation of Aberrant Signalling Pathways 
as Useful Targets for Renal Clear Cell Carcinoma Therapy 113 
 
 
Fig. 1. Schematic representation of the signalling pathways contributing to angiogenesis  
and cell proliferation in RCC and the targeted agents which inhibit them. HIF activation 
upregulates the expression of VEGF, PDGF, EGF and Ang-2. Binding of these ligands to 
their receptors induces downstream activation of MAPK signalling, resulting in 
angiogenesis. Abbreviations; VHL: Von Hippel Lindau; HIF: hypoxia-inducible factor; 
mTOR: mammalian target of rapamycin; PI3K: phosphoinositol-3 kinase; VEGF(R): vascular 
endothelial growth factor (receptor); PDGF(R): platelet-derived growth factor (receptor); 
EGF(R): epidermal growth factor (receptor); TGF-ǃ: transforming growth factor beta;  
Ang-2: angiopoietin 2. Inhibitory arrows (┤) show clinically available or in development 
therapeutic agents for the treatment of RCC and mRCC. 
2.1.2 Aflibercept 
Aflibercept is an engineered fusion protein designed to interact with all isoforms of VEGF 
and to placental growth factor (PLGF), thereby preventing them from binding to VEGFRs. It 
is composed of the extracellular domain 2 of VEGFR1 and extracellular domain 3 of 
VEGFR2 fused to an Fc segment of human IgG1 (Wulff et al., 2002). Aflibercept appears to 
have a greater affinity for VEGF than bevacizumab, resulting in a more complete 
obstruction of VEGF signalling. This together with the fact that aflibercept binds to PLGF 
while bevacizumab does not, may explain why preclinical studies have shown aflibercept to 
be more effective than bevacizumab (Kim et al., 2002). 
www.intechopen.com
 
Renal Cell Carcinoma 114 
2.2 Receptor tyrosine kinase inhibitors (RTKIs) 
The intracellular kinase activity of growth factor receptors also provides an attractive target 
for therapeutic intervention. Three receptor tyrosine kinase inhibitors are currently available 
for the treatment of clear cell RCC and many more are in development (Figure 1). By 
targeting the intracellular tyrosine kinase domain of multiple growth factor receptors these 
drugs inhibit not only the VEGF pathway but also the platelet derived growth factor (PDGF) 
pathway as well as other kinases critical for proliferation and angiogenesis. 
2.2.1 Sorafenib 
Sorafenib was the first multi-targeted kinase inhibitor approved for the treatment of patients 
with cytokine-refractory advanced RCC or mRCC. It is a potent small molecule dual-action 
inhibitor, first identified in in vitro assays as an inhibitor of Ras signalling. Sorafenib also 
inhibits VEGFRs and PDGFRs (Wilhelm et al., 2004). As multiple kinases are inhibited by 
sorafenib it is difficult to determine the relative contribution of each target to the anti-
tumour activity of this drug. Preclinical studies in a variety of cancer models suggest 
sorafenib acts on both tumour cells and tumour vasculature by inhibiting cellular 
proliferation and angiogenesis pathways (Wilhelm et al., 2008). 
Sorafenib’s approval by the FDA in 2005 was as a result of a phase III trial namely; 
Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET). All 
participants had advanced RCC and had experienced disease progression in spite of the 
then standard cytokine therapy. Patients were randomly assigned to receive sorafenib or 
placebo (Escudier et al., 2007b). At the first interim analysis the ORR was 10% for sorafenib 
compared with 2% for placebo. Also, sorafenib treated patients had a significant PFS 
advantage of 5.5 months versus 2.8 months for the placebo group. At this point those 
patients initially assigned to receive placebo were allowed to switch to sorafenib, potentially 
obscuring differences in end point results. In fact the final analysis of all patients registered 
in the trial did not show a statistically significant difference in the OS of the initial intent-to-
treat population (17.8 vs. 15.2 months in sorafenib and placebo treated patients, 
respectively). However, a secondary analysis was performed in which patients who crossed 
over to sorafenib after initial treatment with placebo were censored. This demonstrated a 
significant benefit for sorafenib treatment with a median OS of 17.8 months compared to 
14.3 months for placebo (Escudier et al., 2009). In terms of side effect profile sorafenib 
treated patients reported fewer adverse effects and a better overall quality of life than those 
receiving IFN-ǂ. Both hypertension and skin toxicity, in general, are common manifestations 
of toxicity with multiple tyrosine kinase inhibitors, with incidences of 17% and 40% 
respectively, outlined in the TARGET trial. Other adverse effects associated with sorafenib 
treatment are diarrhea (Escudier et al., 2007b), and an additive loss of muscle mass above 
that usually observed in patients with advanced cancer (Antoun et al., 2010). 
2.2.2 Sunitinib 
Sunitinib is a RTKI designed to prevent cells from responding to the elevated level of pro-
angiogenic signals associated with RCC. It is an orally available, small molecule, multi-
targeted kinase inhibitor with activity against VEGFRs, PDGFRs, fms-like tyrosine kinase 
receptor-3 (FLT-3) and stem cell factor receptor (c-KIT). Sunitinib is classified as an ATP 
competitive inhibitor. It received accelerated approval by the FDA in 2006 based on 
responses in patients with mRCC who had failed cytokine therapy. Regular approval was 
obtained in 2007 as a result of a phase III study evaluating sunitinib as a first-line therapy 
www.intechopen.com
Exploitation of Aberrant Signalling Pathways 
as Useful Targets for Renal Clear Cell Carcinoma Therapy 115 
compared with IFN-ǂ. Results of the trial demonstrated a considerable advantage for 
sunitinib over IFN-ǂ and both OS rates and PFS were significantly higher for the sunitinib 
treated group (Motzer et al., 2007a; Motzer et al., 2009). Sunitinib is now the standard of care 
for initial therapy of good to moderate prognosis mRCC patients. OS of over two years is a 
marked improvement on the one year OS rates observed before the advent of targeted 
kinase inhibitor therapy (Motzer et al., 2009).  
As sunitinib inhibits multiple kinases and therefore blocks several signalling pathways, 
numerous side effects are associated with treatment. These, however, are favourable when 
compared to the significant toxicity profile associated with the previous therapeutic option 
for RCC i.e. immunotherapy. In the phase III trial which led to the approval of sunitinib, 
slightly different toxicity profiles were observed between the two treatment groups. 
Sunitinib treated patients more commonly experienced diarrhea, hypertension, hand-foot 
syndrome, neutropenia and thrombocytopenia while fatigue occurred more commonly in 
the IFN-ǂ group. Overall, however, patients who received sunitinib reported a better quality 
of life compared to patients treated with IFN-ǂ. 
2.2.3 Pazopanib 
Pazopanib is the latest multiple kinase inhibitor approved for the first-line treatment of 
patients with advanced RCC. It inhibits signalling by VEGFRs, PDGFRs, and c-KIT by 
competitively binding to the ATP enzymatic pocket of the RTK. Pazopanib differs from 
sunitinib and sorafenib as the range of targets it potently inhibits is narrower. FDA approval 
followed a phase III trial involving clear cell (or predominately clear cell) RCC patients with 
no previous treatment history (54%), or who had progressed following a single prior 
cytokine treatment (46%) (Sternberg et al., 2010). Patients were randomized to receive either 
pazopanib or placebo daily. In the overall population the primary end point of PFS was 
significantly higher in the pazopanib group compared to placebo (9.2 vs. 4.2 months). The 
ORR for the pazopanib group was 30%. Although a non-significant improvement in median 
OS of 22.9 months for the pazopanib group versus 20.5 months for the placebo group was 
reported, this analysis had been confounded by the early and high level of patient cross-
over from placebo to pazopanib upon progression (Sternberg, 2010). 
The toxicity profile associated with pazopanib treatment is similar to both sunitinib and 
sorafenib. The most common effects observed include hypertension, diarrhea, nausea, hair 
depigmentation and asthenia. Clinical trials cannot easily be compared, however, as evident 
from a phase III trial of pazopanib which demonstrated lower incidence of hand-foot 
syndrome, diarrhea and asthenia compared with sunitinib and sorafenib. Conversely, the 
incidence of hypertension associated with pazopanib treatment in the phase III trial is high 
(40%) when compared to sunitinib and sorafenib trials (Lang & Harrison, 2010).  
2.2.4 In development 
The new generation of RTKIs in development for the treatment of RCC display greater 
potency and selectivity for VEGFRs compared to the established kinase inhibitors 
discussed above. It is hoped that this increased potency and high specificity will give rise 
to enhanced anti-tumour activity. Furthermore, the absence of off-target (non-VEGFR) 
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2.2.5 Axitinib (AG-013736) 
Axitinib is an orally available RTKI. Picomolar concentrations are sufficient for axitinib to 
inhibit VEGFRs, while it inhibits PDGFR-ǃ and c-KIT at low nanomolar concentrations (Hu-
Lowe et al., 2008). In this study and others (Inai et al., 2004) axitinib in mouse models has 
demonstrated anti-tumour, anti-angiogenic and anti-metastatic properties as well as having 
an ability to induce central necrosis. Axitinib is now being looked at for the second-line 
treatment of advanced RCC. In a phase II trial of patients with cytokine-refractory mRCC 
(Rixe et al., 2007), axitinib displayed an ORR of 44.2% and median PFS of 15.7 months, 
greater than any agent investigated for mRCC treatment to-date. However, this efficacy has 
not been examined in comparative trials with other targeted agents.  
2.2.6 Cediranib (AZD2171) 
Cediranib is an ATP-competitive inhibitor of RTKs and like axitinib is a potent inhibitor of 
VEGFRs and PDGFR-ǃ at subnanomolar concentrations (Gomez-Rivera et al., 2007; Takeda 
et al., 2007). In a recent placebo controlled phase II trial, a median PFS of 12.1 months was 
observed in patients treated with cediranib compared to 2.7 months for those who received 
placebo. Furthermore, the mean change in tumour size in patients receiving cediranib was a 
20% decrease versus a mean increase of 19% for patients randomized to placebo (Bhargava 
& Robinson, 2011). 
2.2.7 Tivozanib (AV-951) 
Tivozanib is an orally active RTKI and is selective for VEGFRs at picomolar concentrations 
(Nakamura et al., 2006). In a phase II trial, clear cell RCC patients who had undergone 
nephrectomy displayed an ORR of 32% to 1.5 mg tivozanib daily. The median PFS for 
patients was 14.8 months (Bhargava et al., 2010). This potency combined with the selectivity 
of tivozanib for VEGFRs reduces the inhibition of off-target kinases, resulting in less 
toxicity. The most common side effects reported in this trial were hypertension and 
dysphonia while incidences of other toxicities usually associated with RTKIs (fatigue, 
diarrhea and hand-foot syndrome) were low. The occurrence of fewer toxicities together 
with the specificity of tivozanib allows it to be safely combined at full dose and scheduled 
with another targeted agent. For example, preliminary results of a phase I trial combining 
tivozanib and the mTOR inhibitor temsirolimus in mRCC patients reported no dose limiting 
toxicities (Fishman et al., 2009). 
2.2.8 Regorafenib 
Regorafenib is a potentially significant multi-kinase inhibitor in that it inhibits the 
traditional targets of VEGFRs, PDGF-ǃ and fibroblast growth factor (FGF)-1, as well as the 
endothelium specific receptor tyrosine kinase Tie-2. The inhibition of targets both within 
and external to the VEGF axis may offer valuable therapeutic advantages when it comes to 
avoiding resistance and enhancing the efficacy of targeted therapy. A phase II trial of 
regorafenib in mRCC patients showed that those receiving regorafenib had a 27% partial 
response and a 42% stable disease rate (Eisen et al., 2009).  
2.2.9 Dovitinib (TKI258) 
Dovitinib is also a promising agent targeting VEGFRs, PDGFRs, FLT3 as well as FGF 
receptors namely FGFR3. This is significant as not only does the FGF angiogenic signalling 
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pathway provide a potential mechanism of resistance to VEGF therapy, activating mutations 
or upregulation of FGF/FGFRs have been identified in RCC (Emoto et al., 1994). Members 
of the FGF family are involved in proliferation, differentiation and migration of a range of 
cell types. A phase II study of dovitinib in previously treated advanced RCC or mRCC 
patients has reported results which include a median PFS and OS of 6.1 and 16 months, 
respectively (Angevin et al., 2011). 
3. Targeting EGFR 
Disruption of EGF signalling is a popular therapeutic mechanism in a number of cancer 
types. As the expression of ligands of the EGFR (including EGF and the angiogenesis 
promoting transforming growth factor (TGF)-ǃ) is upregulated by VHL inactivation, the 
validity of this approach in clear cell RCC was explored in a number of trials. In single-agent 
EGFR inhibitor trials, gefitinib (a selective EGFR TKI) and cetuximab (a recombinant mouse-
human mAb) were administered as monotherapy. Neither agent demonstrated a complete 
or partial response (Staehler et al., 2005). In a randomized phase II trial, clear cell RCC 
patients received either bevacizumab or bevacizumab plus the EGFR inhibitor erlotinib. The 
results showed identical median PFS and ORR between the two groups (Bukowski et al., 
2007). EGFR inhibition therefore does not appear to be a viable approach for the treatment 
of clear cell RCC. A possible reason for this may be the rarity of EGFR mutations in RCC, 
when compared to other cancers (Dancey, 2004). Furthermore, the activators of EGFR 
signalling which are upregulated in RCC can also initiate VEGFR signalling, making the 
inhibition of EGFR alone insufficient to disrupt tumour proliferation and angiogenesis. 
4. Targeting PDGF 
Members of the PDGF family include PDGF-A, -B, -C and –D and mediate their effects 
through binding to PDGFR-ǂ and –ǃ leading to the activation of various signalling 
pathways giving rise to tumour growth (Guo et al., 2003; Pietras et al., 2003). High levels of 
PDGF-D has been shown to be associated with RCC and its progression has been linked to 
PDGF-D/PDGFR-ǃ signalling and PDGFR-ǂ expression (Sulzbacher et al., 2003). Although 
there is not a wealth of data published on PDGF and PDGFR in RCC there are currently 
many drugs either clinically available or in development that target this RTK as outlined 
above and in Figure 1. 
5. Limitations of currently available targeted agents 
Comparison of the relative benefit of each targeted treatment in advanced RCC and mRCC 
is exceptionally difficult. Trials conducted targeting RTKs involved varied patient 
populations with differences in prior treatment status, prognosis and histology of RCC. 
According to Flaherty & Puzanov the easiest comparison is ORR. This comparison identifies 
two groups: bevacizumab and sorafenib generate a response rate of ≤10%, while sunitinib 
and pazopanib induce a response in ≥30% of patients. However, this does not reflect any 
clinical benefit as higher response rates do not appear to be associated with improved PFS 
or OS (Flaherty & Puzanov, 2010).  
Resistance is a major problem with both older and newer therapies as well as mono and 
poly therapies. Few complete responses are associated with any of the targeted therapies 
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discussed. All patients will eventually develop resistance and progress, usually within 8 to 
16 months (Sosman & Puzanov, 2009). A number of mechanisms have been described 
outlining how resistance can occur. Sorafenib, sunitinib and pazopanib therapy is associated 
with a significant increase in VEGF production (Deprimo et al., 2007; Kumar et al., 2007; 
Veronese et al., 2006). Resistance may occur if the increase in VEGF reaches a threshold that 
can overcome the inhibition. Another hypothesis has been examined in animal models of 
tumour angiogenesis. These models outline that the inhibition of VEGF or VEGFR leads to 
upregulation of PDGF and basic FGF (bFGF) production by tumours activating alternative 
pathways for angiogenic signalling (Fernando et al., 2008). Despite the overlap of targets 
and inevitable resistance, however, RCC tumours do not appear to be totally cross-resistant 
to sequential therapy with different agents. In a phase II study, patients who had progressed 
on sunitinib underwent treatment with sorafenib. Objective responses resulted in 10% of 
patients with a median PFS of 16 weeks (Di Lorenzo et al., 2009). A possible explanation is 
that when the initial inhibitor is removed (once resistance has occurred and the tumour has 
progressed), cells revert back to VEGF signalling.  
Presently, it is hoped that combination therapies for the treatment of patients with RCC will 
see improvements in PFS, ORR and OS greater than those seen with any single agent. There 
are two options for the combination of targeted therapies i.e. vertical blockade and horizontal 
blockade. Vertical blockade involves targeting several steps along a single signalling pathway. 
This is an attractive option in treatment of RCC combining drugs which inhibit hypoxia-
inducible factor (HIF) translation, VEGF or VEGFR. This approach could provide an 
opportunity to overcome the resistance associated with increased levels of VEGF. A phase I 
trial evaluated the potential benefit of combining sorafenib with bevacizumab in mRCC 
patients (Sosman, 2008). Due to toxicity, the dosage of both agents had to be reduced from 
their usual levels to half the recommended dose of bevacizumab and one-quarter the usual 
dose of sorafenib. Despite this a 50% response rate was observed, a vast improvement on the 
10-15% achieved with full doses of each agent alone. The combination strategy of horizontal 
blockade entails simultaneously targeting more than one signalling pathway crucial for 
tumour cell survival and proliferation. Horizontal blockade is an appealing option as 
combining VEGFR inhibitors with other tyrosine kinase inhibitors may prove useful in 
preventing resistance by the mechanism of alternative angiogenic pathways. 
6. PI3K/AKT/mTOR signalling pathway 
The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin-
pathway (PI3K/AKT/mTOR-pathway) is one of the most common aberrant pathways 
activated in cancer, regulating many known oncogenic pathways including apoptosis, 
proliferation and cell migration  (Carracedo & Pandolfi, 2008; Klein & Levitzki, 2009; Inoki 
et al., 2005). Activation of PI3K occurs at the cell membrane in response to several RTKs 
including the EGFR, the insulin-like growth factor receptor (IGFR) and the PDGFR leading 
to the production of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3). 
Levels of PIP3 are tightly regulated by the tumour suppressor phosphatase and tensin 
homolog (PTEN), serving as the negative regulator of the PI3K/AKT/mTOR pathway. AKT 
is recruited to the cell membrane by PIP3 and phosphorylated to its fully activated form by 
phosphoinositide dependent protein kinase 1 (PDK1). Activated AKT can directly activate 
mTOR by phosphorylation or indirectly through inactivation of the tuberous sclerosis 
complex 2 (TSC2) which normally inhibits mTOR (Figure 2).  
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mTOR is a 290kDa serine/threonine protein kinase and is highly conserved from fungi to 
mammals. It forms multimolecular complexes and plays a key role in diverse signalling events 
such as growth, proliferation, survival, angiogenesis and protein synthesis (Dowling et al., 
2010).  mTOR responds to a range of diverse stimuli including growth factors, cytokines, and 
hormones but also acts as an important sensor of cellular stresses imposed by hypoxia, pH or 
osmotic alterations, heat shock, oxidative stress and DNA damage. Defects in signalling 
components upstream of mTOR including excessive growth factor receptor activation or 
mutation correlates with a more aggressive tumour and a worse prognosis (Faivre et al., 2006). 
mTOR exists as two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2) (Figure 2). Regulation of mTOR activation is controlled by two components of the 
tuberous sclerosis complex (TSC) comprising TSC1 (hamartin) and TSC2 (tuberin). When they 
heterodimerise mTOR is inhibited and can no longer phosphorylate downstream substrates 
(Dancey, 2005). Phosphorylation of TSC2 by AKT, however, promotes dissociation of the 
TSC1/TSC2 complex which activates the guanosine triphosphate Rheb. Rheb activity 
subsequently activates mTORC1. mTORC1 is bound to raptor (regulatory-associated protein 
of mTOR), mLST8 (mammalian lethal with sec 13 protein 8), also known as GǃL and PRAS40 
(proline-rich AKT substrate 40kDa) which is phosphorylated by AKT causing its dissociation 
from raptor and its subsequent activation. mTORC2 complexes with rictor (rapamycin-
insensitive companion of mTOR), mSIN1, mLST8 and Protor-1 or Protor-2. Both complexes 
phosphorylate the hydrophobic motifs of AGC kinase family members. mTORC1 
phosphorylates S6K and the inhibitory binding protein 4E-BP1 at Thr37 and Thr 46 which acts 
as a priming event essential for the phosphorylation of Ser65 and Thr70 leading to the release 
of eIF4E and subsequent assembly of the eIF4F complex (Gingras et al., 2001).  Activation of 
S6K in turn leads to phosphorylation of inhibitory sites (Ser636 and 639) on the insulin 
receptor substrate-1 (IRS-1), thereby suppressing IRS-1 mediated activation of the PI3K/AKT 
pathway. mTORC2 activation leads to phosphorylation of AKT, SGK1 and PKC which control 
cell survival and cytoskeletal organization (Figure 2). 
mTORC1 is frequently dysregulated in cancer (Guertin & Sabatini, 2007). Loss or 
inactivation of tumour suppressors such as p53, liver kinase B1 (LKB1), PTEN and TSC1/2 
which antagonise PI3K-dependent activation of mTORC1 can promote tumourigenesis via 
increased signalling through mTORC1 (Sabatini, 2006; Shaw et al., 2004). Moreover, 
increased levels and/or phosphorylation of downstream targets of mTORC1 have been 
reported in various human malignancies in which they correlate with tumour 
aggressiveness and poor prognosis (Guertin & Sabatini, 2007; Mamane et al., 2006). 
Collectively these studies suggest that aberrant mTORC1 signalling is linked to 
dysregulated control in cancer and for this reason the spotlight has been shone on mTORC1 
as a possible therapeutic target for anti-cancer therapy. 
6.1 mTOR and RCC 
As outlined above the signalling network controlled by the PI3K/AKT/mTOR axis is very 
often found to be dysregulated in human malignancy. There is a wealth of data to support 
the notion that signalling through mTOR is dysregulated in RCC. This makes this cancer 
type in particular an attractive target for mTOR inhibitor therapy. RCC demonstrates 
increased phosphorylation of AKT, S6K1 and mTOR as well as increased expression of 
PTEN and disrupted TSC complexes (Pantuck et al., 2007). mTOR activation ultimately 
leads to increased production of angiogenic factors leading to a highly vascularised tumour 
which is evident in RCC.  
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Fig. 2. Schematic representation of mTOR signalling, phosphatidylinositide 3’OH-
kinase/AKT/mTOR signalling, Wnt/ǃ-catenin signalling, HGF signalling and core NOTCH 
signalling pathways. In relation to growth factor signalling, PI3K activates downstream 
mTORC1 giving rise to HIF-1ǂ activation, which in turn switches on gene expression 
required for angiogenesis and cell proliferation in endothelial cells. HGF binding to MET 
leads to its phosphorylation and subsequent recruitment of adapter proteins such as Gab1, 
Gab2, SHC, STAT3 and PI3K with downstream activation of Ras/MAPK and PI3K/AKT 
pathways. Wnt pathway activation leads to hypophosphorylated ǃ-catenin where it 
translocates into the nucleus and forms a complex with TCF. Ligand binding to the Notch 
receptor leads to release of the intracellular domain (ICD) of Notch. Notch ICD 
subsequently translocates into the nucleus, where it forms a complex with essential cofactors 
such as the transcription factor CSL. This complex mediates the transcription of target genes 
such as HES and HEY. Abbreviations; RTK: receptor tyrosine kinase; PI3K: 
phosphatidylinositol 3-kinase; PDK1: phosphoinositide dependent protein kinase 1; PTEN: 
phosphatase and tensin homolog; mTOR: mammalian target of rapamycin; TSC: tuberous 
sclerosis complex; mLST8: mammalian lethal with sec 13 protein 8; PRAS40: prolin-rich AKT 
substrate 40 kDa; IRS-1: insulin receptor substrate-1; VHL: von Hippel-Lindau; HIF: hypoxia 
inducible factor; TCF; T cell factor; HGF: hepatocyte growth factor; CSL: CBF1, Suppressor 
of hairless, Lag-1; HES: hairy enhancer of split; Hey: hairy enhancer of split related with 
YRPW. Inhibitory arrows (┤) show clinically available or in development therapeutic targets 
for the treatment of RCC and mRCC. 
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mTOR inhibitors were originally developed as immunosuppressants for patients 
undergoing transplantation with rapamycin (also known as sirolimus or Rapamune®) being 
the first mTOR inhibitor identified. Clinical experience and subsequent trials identified the 
anti-proliferative (Schmelzle & Hall, 2000) and anti-angiogenic (Del Bufalo et al., 2006) 
properties of these agents in various cancer types, including RCC. This is of particular 
clinical importance as RCC demonstrates significant uncontrolled angiogenesis. More 
specifically mTORC1 activity is inhibited by rapamycin and associated analogs 
(temsirolimus, everolimus and ridaforolimus) which are collectively termed rapalogs. 
mTORC2, however, is largely insensitive to rapalogs, although prolonged treatment may be 
able to reduce mTORC2 activity in some cell types (Sarbassov et al., 2006). 
6.1.1 mTOR inhibitors-rapamycin 
Rapamycin is a naturally occurring macrolide triene antibiotic that acts as a specific, 
allosteric inhibitor of mTORC1 (Hay & Sonenberg, 2004). Rapamycin either associates with 
the immunophilin FKBP12 (FK 506-binding protein of 12 kDa) and the resulting complex 
interacts with the FRB (FKBP12-rapamycin binding) domain located in the C-terminus of 
mTOR or directly to FRB. This binding prevents the binding of mTORC1 to raptor which is 
thought to uncouple it from its substrates 4E-BPs and S6Ks (Oshiro et al., 2004). The ability 
of rapamycin to suppress both cellular proliferation and growth through its interaction with 
mTORC1 indicated that it could be used as an anti-cancer agent (Faivre et al., 2006). This 
lead to the development of rapamycin analogs (rapalogs) which display the same 
pharmacodynamics as the parent drug but have improved pharmacokinetic properties.  
6.1.2 Temsirolimus 
Temsirolimus (Torisel®), also known as CCI-779, is a macrocyclic lactone and a water-
soluble ester prodrug of rapamycin. It is administered by i.v. injection, is rapidly cleared 
from the plasma and is converted by CYP4503A4/5 into rapamycin. It binds with high 
affinity to the immunophilin FKBP12 and selectively inhibits mTORC1 with no effect on 
mTORC2 (Le Tourneau et al., 2008). Inhibition of mTORC1 kinase activity results in 
decreased phosphorylation of S6K and 4E-BP1. In addition by inhibiting mTORC1 it has 
been shown to reduce expression of HIF-1ǂ and -2ǂ which leads to decreased VEGF and 
PDGF expression (Thomas et al., 2006). Thus, the clinical efficacy of temsirolimus reflects 
bimodal phamacodynamics resulting in null signalling of RTK cascades and inhibition of 
protein synthesis can result in inhibition of cell cycle and tumourigenesis. Temsirolimus was 
approved as first-line therapy for patients with mRCC in the US and Europe in May 2007 
demonstrating improved efficacy in poor-prognosis patients in comparison with IFN-ǂ 
(Hudes et al., 2009). The efficacy of temsirolimus in the second-line setting remains unclear. 
However, recently it has demonstrated disease control rate of 70% and overall median time 
to progression of four months in intermediate to poor-prognosis patients with VEGF-
refractory mRCC (Mackenzie et al., 2011).  Side effects of the drug include diarrhoea, 
asthenia stomatitis, rash, nausea, anorexia, hypertension, dyspnea, hyperglycaemia, 
hypercholesterolemia and anemia.  
6.1.3 Temsirolimus plus immunotherapy combination  
Temsirolimus was first investigated as combination therapy with IFN-ǂ in phase I/II study 
(Motzer et al., 2007b). This study revealed that the combination of the two had an accepted 
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safety profile and displayed anti-tumour activity in patients with mRCC. A pivotal phase III 
trial was also carried out comparing temsirolimus or temsirolimus plus IFN-ǂ with IFN-ǂ 
alone in patients with mRCC. In summary, the median OS time was significantly longer 
with temsirolimus alone than with IFN-ǂ alone (10.9 months versus 7.3 months, 
respectively), and combination therapy with temsirolimus and IFN-ǂ did not lead to a 
significantly longer median OS time than with IFN-ǂ alone (8.4 months versus 7.3 months, 
respectively) (Hudes et al., 2007).  
6.1.4 Temsirolimus plus anti-angiogenics combination 
Phase I studies examining the efficacy of temsirolimus with sunitinib have not shown 
sufficient safety to-date. Trials using temsirolimus in combination with sunitinib and 
temsirolimus in combination with sorafenib were discontinued owing to significant toxicity 
(Patel et al., 2009). The efficacy of temsirolimus plus bevacizumab has also been studied but 
again based on toxicity profiles a phase II trial has indicated that this combination cannot be 
recommended for patients with mRCC (Negrier et al., 2011). In summary, the combined 
usage of temsirolimus and anti-angiogenic agents has proved disappointing to date, phase 
III trials are still continuing whose results may shed light on possible best practice for 
combination therapy in the near future.    
6.2 Everolimus 
Everolimus (Afinitor®) is an orally bioavailable hydroxyethyl ester of rapamycin. Like 
temsirolimus it is an inhibitor of mTORC1 and was approved on March 30th, 2009 for 
patients suffering from advanced RCC following failure when treated with previous TKI 
therapy (de Reijke et al., 2009). It has now become the standard second-line agent after the 
approved first-line drugs sunitinib and/or sorafenib (Soulieres, 2009).  
6.2.1 Everolimus plus anti-angiogenics combination 
The combination of everolimus and the VEGFR TKIs are showing promise in initial studies. 
A phase II study of everolimus plus sorafenib has been prompted following successful 
completion of a phase I trial with the combination of both demonstrating acceptable toxicity 
and evidence of anti-tumour activity in patients with previously untreated mRCC 
(Harzstark et al., 2011). Similarly, a phase II trial of everolimus plus sunitinib is warranted 
following successful maximum-tolerated dose of everolimus plus sunitinib in patients with 
mRCC (Kroog et al., 2009). In contrast, everolimus plus imatinib is not recommended for 
future studies following results from a phase II study in previously treated patients with 
mRCC as the combination did not demonstrate a three month PFS rate of 49%, which did 
not meet the specified criteria for continuation (Ryan et al., 2011). Finally, in a phase II trial 
with two different mRCC patient cohorts, one with and one without prior TKI treatment, 
everolimus plus bevacizumab was active and well tolerated (Hainsworth et al., 2010). This 
regimen which uses full doses of each agent, is being evaluated as first-line therapy in a 
phase II study, RECORD (Renal Cell Cancer Treatment With Oral RAD 001 Given Daily)-2. 
6.3 Ridaforolimus 
The mTOR inhibitor, ridaforolimus (formerly deforolimus), is yet another promising 
rapamycin analog in RCC treatment but not yet approved. Ridaforolimus (also known as 
AP23573), a non-prodrug of rapamycin, has demonstrated prominent anti-proliferative 
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activity against a range of cancers (Hartford et al., 2009). The most common side effects 
associated with ridaforolimus to-date include stomatitis, fatigue, diarrhoea and 
thrombocytopenia. Important additional information such as OS and the safety profile of 
ridaforolimus has yet to be identified. 
6.4 Combination therapy 
At present there are numerous ongoing and planned studies evaluating the efficacy of both 
temsirolimus and everolimus with other targeted therapies including VEGF ligand 
competitors, VEGFR inhibitors, AKT inhibitors, p70S6R inhibitors, tubulin inhibitors, IGF-
1R antagonists and Bcr-ABL antagonists (Pal & Figlin, 2011). Information pertaining to the 
successes associated with these exploratory trials is limited at present. 
6.5 New mTOR inhibitors  
Presently, temsirolimus and everolimus are approved for the treatment of mRCC. Despite 
their efficacy there are some drawbacks including resistance but also the fact that they are 
both specific mTORC1 inhibitors that lack activity against mTORC2. This allows the latter to 
activate AKT. Indeed, increased activation i.e. phosphorylation of AKT has been 
documented in tumour biopsies isolated from patients treated with rapalogs (O'Reilly et al., 
2006). In addition the crosstalk with other pathways such as MEK/ERK on AKT could limit 
the efficacy of mTOR inhibitors. There are reports of newer drugs targeting mTORC2 as well 
as MAPK interacting pathways. New mTOR inhibitors are not rapalogs but are small 
molecule inhibitors resembling TKIs. They bind competitively and reversibly to the mTOR-
ATP binding pocket blocking the enzymatic activity of the kinase. Compounds such as 
PP242, Torin1, WYE-354, WYE-125132 (WYE-132) and Ku-006379 suppress both mTORC1 
and mTORC2 displaying more dramatic effects on cell growth, proliferation and cell cycle 
than rapamycin. This has been attributed to suppression of mTORC2 mediated AKT 
phosphorylation at Ser 473 and greater inhibition of 4E-BP1 phosphorylation (Thoreen et al., 
2009). Active site mTOR inhibitors have the potential to be potent anti-cancer drugs as they 
inhibit mTORC2 activity which rapamycin and its analogs do not but also because they 
counteract the activation of AKT which can occur as a result of rapamycin-mediated 
disruption of the mTOR/S6K/IRS-1 negative feedback loop. To-date these potentially 
effective cancer therapeutic agents have yet to be investigated in patients with RCC or 
mRCC. 
7. Targeting mTOR upstream moieties – PI3K 
PI3K is a lipid kinase that converts phosphatidylinositol bisphosphate to PIP3. PI3K further 
recruits PDK1 and AKT to the cell membrane where PDK1 activates AKT. Because of its 
location upstream of mTOR, it has become another attractive target for treatment of patients 
with RCC to be used solely or in combination with existing mTOR inhibitors.  Recently, 
activation of the PI3K pathway has been shown to be directly linked to adverse clinical 
outcomes in patients with RCC (Merseburger et al., 2008). The PI3K inhibitor prototypes 
wortmannin and LY294002 have been shown to decrease AKT activation and significantly 
reduce cell growth in vitro particularly in PTEN-null or PI3K-overexpressing RCCs with the 
latter also demonstrating in vivo tumour regression (Sourbier et al., 2006). Given that PI3K is 
highly expressed in RCC metastases, which are themselves radioresistant, newer generation 
PI3K inhibitors such as PX-866, with better bioavailability and less toxicity, may show utility 
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as radiosensitizers in RCC metastases. Another chemotherapeutic drug, PI-103, has recently 
been shown to independently inhibit both PI3Kǂ and mTOR (Fan et al., 2006) thereby 
overcoming a potential disadvantage of rapamycin in the treatment of AKT-dependent 
tumors. In fact GDC-0941 which is derived from PI-103 has demonstrated improved 
bioavailability and partial response in breast and ovarian cancer patients.  Ongoing studies 
using PI3K and dual PI3K/mTOR inhibitors such as SAR245408, SAR245408, NVP-BKM120 
and NVP-BEZ235 modified for clinical use are ongoing (Maira et al., 2008). These have yet to 
be tested in patients with RCC. 
7.1 PDK1 
Similar to PI3K, a key mediator of AKT activation, PDK1 is poised to respond to targeted 
inhibition with blockade of AKT signalling (Figure 2). Both highly specific inhibitors, such 
as AR-12 (Arno), and inhibitors with dual function on PDK1/PI3K or PDK1/AKT are in 
development (Najafov et al., 2010).  These targets present another potentially robust way to 
render the AKT pathway completely inhibited, mitigating the confounding issues of 
inhibition of each of the AKT family members. 
7.2 AKT 
AKT, also known as protein kinase B (PKB), can be activated by a number of mechanisms 
including PIP3 activation of PDK1 at Thr308 and at Ser473 by mTORC2 (Figure 2). 
Decreased expression of the inhibitory PTEN can also activate AKT (Hara et al., 2005). Upon 
phosphorylation (p-)AKT is known to interact with a large set of substrates, including 
mTOR and through inactivation of the TSC impacts many key cellular processes such as cell 
cycle progression and apoptosis, both of which play a vital role in oncogenesis. Recently, p-
AKT expression was shown to be correlated with pathologic variables and survival, with 
higher levels of cytoplasmic p-AKT expression compared with nuclear p-AKT in primary 
RCC  (Pantuck et al., 2007).  Recently, a specific p-AKT (S473) inhibitor, WYE-132, has been 
tested on RCC cell lines and achieved complete regression of A498 large tumours when 
administered with bevacizumab (Yu et al., 2010). 
8. Targeting downstream moieties-HIF-1α 
RCC is closely linked to mutations in the von Hippel-Lindau (VHL) gene. A deletion of one 
allele of VHL has been identified in >90% of patients with sporadic clear cell RCC (Gnarra et 
al., 1994). The remaining VHL allele is also commonly inactivated by a deletion event or 
altered methylation (Nickerson et al., 2008). In normal cell conditions, the VHL protein is a 
direct inhibitor of the activity of a key regulator of responses to hypoxia i.e.  HIF. HIFs are 
heterodimers and contain an ǂ and a ǃ subunit. VHL targets the HIF-ǂ isoform for 
proteasomal degradation. This prevents it from translocating to the nucleus and binding to 
HIF-ǃ which would result in the induction of over 200 target genes that contain hypoxia-
response elements in their promoters. The best described of the numerous HIF targets are 
growth factors which promote angiogenesis and proliferation (Figures 1 and 2). Under 
hypoxic conditions, VHL itself is degraded. This stabilizes HIF-ǂ within the cell and allows 
it to accumulate in the nucleus. Here it initiates the expression of genes which promote cell 
survival and growth. The effects of biallelic inactivation of the VHL gene in clear cell RCC 
cells mirror those which result from VHL degradation in response to hypoxia. Expression of 
HIF targets such as VEGF, PDGF, and TGF-ǃ are upregulated.  
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The VHL gene product, pVHL, is an E3 ubiquitin ligase that promotes the proteasomal 
degradation of HIF-1ǂ, -2ǂ and -3ǂ. Consequently, renal carcinomas with mutations in VHL 
have high steady-state levels of HIF expression. Functional studies show that HIF is 
sufficient for transformation caused by loss of VHL, thereby establishing HIF as the primary 
oncogenic driver in kidney cancers (Maranchie et al., 2002). mTOR increases the translation 
of HIF-1 and HIF-2 which in turn can drive the expression of angiogenic factors such as 
VEGF, PDGF-ǃ, bFGF and TGF-ǂ. Thus, much interest has recently focused on targeting one 
or both HIF factor signals for cancer therapy. EZN-2968 is an RNA antagonist that 
specifically binds and inhibits HIF-1ǂ mRNA in vitro and in vivo (Greenberger et al., 2008). 
In this study it proved to be a potent, selective, and durable antagonist of HIF-1 mRNA and 
protein expression resulting in reduced prostate and glioblastoma tumor cell growth. Its 
efficacy in RCC has not yet been investigated. In contrast, targeting heat shock protein 
90(HSP90) with 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) 
which reduces levels of HIF-1ǂ in the setting of VHL loss has shown promising results in 
clinical trials including patients with RCC (Kummar et al., 2010; Ronnen et al., 2006). 
Furthermore, YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (an agent originally 
developed for circulatory disorders) and YC-1 analogs, 1, 3-disubstituted selenolo[3,2-
c]pyrazole derivatives have now been found to repress HIF-1 activity and inhibit renal 
cancer tumour growth (Chou et al., 2010). Lastly, PX-478 (S-2-amino-3-[4'-N,N,-bis(2-
chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride) an inhibitor of 
constitutive and hypoxia-induced HIF-1ǂ levels and thus HIF-1 activity has proven efficacy 
in vitro with different RCC cell lines (Koh et al., 2008).  
8.1 HIF-2α 
HIF-2ǂ, also referred to as endothelial PAS domain protein 1 shares 48% homology with HIF-
1ǂ. Current knowledge pertaining to the regulation of HIF-2ǂ is somewhat lacking when 
compared with HIF-1ǂ. However, the tumourigenic role of HIF-2ǂ has been studied most 
extensively in RCC. Both in vitro and in vivo studies with human kidney tumours suggest that 
HIF-2ǂ is more oncogenic than HIF-1ǂ (Maranchie et al., 2002; Raval et al., 2005).  RCC 
tumours express either HIF-1ǂ and HIF-2ǂ or HIF-2ǂ alone, leaving HIF-2ǂ expression as a 
common point of VHL mutated cancers. Moreover, consistent with this data, HIF-1ǂ 
expression has been shown to decrease in advanced lesions as HIF-2ǂ expression increases 
(Mandriota et al., 2002). Resulting from these observations HIF-2ǂ is now being studied as the 
more important isoform for therapeutic intervention of RCC. Although several potentially 
important drugs targeting HIF-1ǂ have been described (as outlined above) reports of HIF-2ǂ 
are few. One potentially effective drug that needs further investigation is emetine, a protein 
synthesis inhibitor that blocks the translocation of peptidyl-tRNA from the acceptor site to the 
donor site on the riboosome. Emetine is not a novel drug (in fact it has been around for almost 
a century) but has been used for the treatment of bacterial, viral and amoeba Entamoeba 
histolytica infections as well as being used as an antiemetic  (Zhou et al., 2005). It has been 
shown to induce HIF-2ǂ downregulation in the setting of VHL loss in RCC cell lines. Further 
analysis of this drug is necessary for its efficacy in the in vivo setting of RCC. 
9. HIF targets-Ror2 
Regulated receptor tyrosine kinase-like orphan receptor 2 (Ror2) is a member of a family of 
orphan RTKs. Ror2 is found heavily phosphorylated in the kidney of RCC patients and is 
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expressed highly in human RCC cell lines indicating a role for Ror2 in the pathology of RCC 
(Wright et al., 2009). In fact suppressed expression of Ror2 results in reduced expression of 
matrix metalloproteinase (MMP)-2, whose upregulation correlates with advanced stages of 
RCCs (Slaton et al., 2001). Thus, Ror2 represents a promising therapeutic target for patients 
with RCC. Although the direct target of Ror2 kinase activity has yet to be deciphered, it does 
appear to act as a mediator of Wnt signals in the further activation of tumour cell signalling 
events (Figure 2). There are currently no clinically available drugs targeting Ror2 for the 
treatment of RCC. 
9.1 Carbonic anhydrase IX 
Carbonic anhydrase IX (CAIX), a hypoxia-induced protein, is unique in that it is a cell 
surface protein that is present in human tumours but absent from normal tissue (Figure 2). It 
is found to be highly expressed in clear cell RCC and is associated with grade (Genega et al., 
2010). Currently, CAIX is being pursued as a prognostic indicator, diagnostic tool and a 
future potential targeted therapy for the treatment of RCC. Presently, there exists a chimeric 
antibody (cG250) used for its localisation, but also for direct antibody-dependent cellular 
cytotoxicity (ADCC). Thus, it has progressed through phase 1 (Davis et al., 2007), phase 2 
(Bleumer et al., 2004), and is presently undergoing a phase 3 trial (NCT00087022) in patients 
with RCC.  In addition, cG250 accumulation in RCC lesions is extremely high and so is 
being investigated as a strategy to deliver tumour-sterilising radiation doses with cG250 as a 
carrier molecule (Divgi et al., 2004). Furthermore, preliminary research with dendritic cells 
loaded with CAIX-derived peptides have shown to activate the cellular and humoral 
immune system in patients with cytokine refractory RCC (Uemura et al., 2006). Large 
prospective trials, however, are required to establish dendritic cell vaccination with CAIX–
derived peptides or indeed direct vaccination with these peptides.  
9.2 Angiopoietins and Tie-2 
Angiopoietin/Tie-2 signalling pathways are important together with VEGF/VEGFR in the 
process of vascular endothelial growth for angiogenesis (Figure 1). Due to the highly 
vascular nature of RCC identifying new anti-angiogenic agents is highly desirable in an 
effort to try and treat this largely refractory cancer. One such target is Tie-2, an endothelium-
specific tyrosine kinase, which serves as a receptor for the family of angiopoietin ligands, 
angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), pro-angiogenic targets of HIF 
transcriptional activity. Binding of the former induces autophosphorylation of Tie-2, the 
latter antagonizes the actions of Ang-1 by competitively binding to Tie-2 without activating 
it.  Ang-1 plays an important role in the assembly of newly formed vasculature and in the 
maintenance of vascular integrity. The role of Ang-2 in angiogenesis is highly dependent on 
the presence of other angiogenic factors, particularly VEGF.  Tie-2 expression has been 
shown to correlate with angiopoietin-2 expression in RCC tumours (Liu et al., 2008).   
Development of therapeutic drugs targeting the Angiopoietin/Tie-2 pathway differ 
somewhat. They may be direct inhibitors of the tyrosine kinase i.e. to target Tie-2, selective 
and non-selective traps to target Ang-1 or -2, or systemic delivery of angiopoietins to induce 
their anti-tumour effects (Huang et al., 2010). Tie-2 kinase inhibitors include CEP-11981 and 
CE-245677, the former is currently being evaluated in an open label phase 1 trial in patients 
with advanced solid tumours. The latter tested in a phase I trial has been discontinued 
owing to unacceptable side effects. There are currently two angiopoietin traps in clinical 
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development. AMG-386 is an anti-angiopoietin peptibody which inhibits the interaction 
between ligands Ang-1 and -2 with the Tie-2 receptor. It is currently undergoing phase II 
trials in combination with sorafenib and sunitinib for the treatment of RCC (Huang et al., 
2010). The second compound PF-4856884 (also known as CVX-060) selectively targets Ang-2 
and in a phase I study demonstrated a significant reduction in RCC tumour blood flow. The 
mild side effect profile of both of these drugs provides an attractive basis for their 
combination with other anti-angiogenic or chemotherapeutic agents.  
9.3 Notch 
Notch signalling controls a variety of processes, involving cell fate specification, 
differentiation, proliferation, and survival (Artavanis-Tsakonas et al., 1999). Mammals have 
four Notch proteins, namely Notch 1-4, that function as receptors for five Notch ligands – 
Jagged1 and 2, and the delta-like ligands (DLL)-1, -3 and -4. Ligand binding leads to at least 
three subsequent proteolytic cleavages that release the intracellular domain (ICD) of Notch. 
Notch ICD subsequently translocates into the nucleus, where it forms a complex with 
essential cofactors such as c-promoter binding factor 1 (CBF1), mastermind-like 1 (MAML1) 
and the transcription factor CSL. This complex mediates the transcription of target genes 
such as that encoding Deltex, genes in the hairy enhancer of split (HES) and HES-related 
families of basic helix-loop-helix transcription factors, and others (Figure 2). Aberrant 
signalling within this pathway has previously been reported in multiple malignancies 
(Miele et al., 2006) including RCC with elevated Notch 1, 3 and Jagged-1 mRNAs (Rae et al., 
2000; Sjolund et al., 2008).  Elevated expression of DLL-4 has also been reported in RCCs 
with reduction of such basal expression having considerable effects on endothelial function 
important in tumour angiogenesis (Patel et al., 2005). Interestingly, Notch signalling can 
lead to either tumour progression or suppression depending on the cellular context (Nicolas 
et al., 2003, Xia et al., 2001). However, in the context of RCC, Notch signalling inhibition has 
lead to inhibition of RCC growth thus indicating a potential novel therapeutic pathway in 
RCC. Presently, there is strong evidence for signalling crosstalk between Notch and HIF-1ǂ. 
Cleaved Notch ICD and HIF-1ǂ appear to play an important point between the two 
signalling cascades (Gustafsson et al., 2005). Moreover, there is recent evidence to support 
Notch signalling linking AKT and hypoxia in melanomas (Bedogni et al., 2008). Whether 
this interaction is pertinent to RCC has yet to be investigated. Inhibition of Notch signalling 
as a strategy for cancer treatment has been proposed in numerous studies (Nickoloff et al., 
2003). Two approaches have been identified; selective strategies involving antisense, mAbs 
and RNA interference; nonselective strategies involving soluble or cell-associated Notch 
decoys, Ǆ-secretase inhibitors, intracellular MAML1 decoys and Ras signalling inhibitors 
(Miele et al., 2006). Currently it is too early to evaluate the true efficacy of these strategies 
and of the different drugs involved but what is known from present findings is that Notch 
inhibition in cancer deserves a thorough investigation including in patients with RCC. 
9.4 Wnt/β-catenin signalling 
Wnts are a family of secreted glycoproteins that regulate a wide range of cellular functions 
such as growth, differentiation, migration and polarity (Moon et al., 2004). Wnt signalling is 
controlled by the transcriptional coactivator ǃ-catenin, which is emerging as a key molecule 
in the pathogenesis of renal cancer. In normal quiescent cells, ǃ-catenin is bound to casein 
kinase 1, glycogen synthase kinase 3ǃ (GSK3), adenomatosis polyposis coli protein and axin. 
This complex controls ǃ-catenin phosphorylation targeting it for proteosomal degradation. 
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Wnt positively regulates ǃ-catenin, preventing its phosphorylation, ubiquitination and 
degradation. Thus, upon Wnt pathway activation hypophosphorylated ǃ-catenin 
translocates into the nucleus and forms a complex with the DNA binding protein T cell 
factor (TCF) (Figure 2). The ǃ-catenin/TCF complex activates transcription of a wide range 
of genes including growth promoting genes such as VEGF (Easwaran et al., 2003) as well as 
the MYC oncogene which shows copy number amplification in RCC (Beroukhim et al., 
2009). Wnt can also mediate its effect on cell growth and tumour promotion by activating 
the mTOR pathway (Inoki et al., 2006). TSC2 is phosphorylated by GSK3 for its activation 
and subsequent inhibition of mTOR. Wnt activates mTOR pathway by inhibiting GSK3.  
There are several papers outlining the involvement of Wnt signalling in RCC. 
Overexpression of ǃ-catenin can induce renal tumours in mice (Sansom et al., 2005). In some 
RCC tumours the APC gene promoter is aberrantly hypermethylated providing a 
mechanism by which ǃ-catenin is liberated  (Battagli et al., 2003). ǃ-catenin is also degraded 
by the E3-ubiquitin ligase activity of VHL and so loss of VHL in RCC has been shown to 
enable HGF-driven oncogenic ǃ-catenin signalling (Peruzzi et al., 2006). In a recent article 
further evidence for the activation of Wnt signalling in RCC was outlined when a deletion of 
CXXC4 a gene coding for Idax, an inhibitor of this pathway, was identified in aggressive 
RCC (Kojima et al., 2009). In addition, various Wnt antagonists such as secreted-Frizzled 
receptor proteins, Dickkopf 2 and Wnt inhibitory factor 1 were found to be hypermethylated 
and thus silenced in RCC (Awakura et al., 2008; Hirata et al., 2009; Kawakami et al., 2009). It 
is also possible that loss of VHL could lead to the combined de-repression of HIFs and ǃ-
catenin which could also lead to RCC (Linehan et al., 2009). Finally, Jade-1 (gene for 
apoptosis and differentiation in epithelia) has been identified as a VHL-interacting protein 
which brings about ǃ-catenin degradation. Thus, Jade-1 is thought to function as a renal 
tumour suppressor (Chitalia et al., 2008). Loss of VHL can bring about a reduction in Jade-1 
levels with subsequent increases in ǃ-catenin levels, providing another caveat by which loss 
of VHL can promote renal tumourigenesis. In summary Wnt signalling has a dual role in the 
pathogenesis of RCC. It induces transcription through activation of ǃ-catenin but also 
activates mTOR signalling driving cellular growth. Thus, Wnt signalling and ǃ-catenin 
provide attractive targets for therapeutic intervention in RCC. At present there are no 
clinically available drugs targeting this pathway in RCC but may become available in the 
near future.  
10. HGF/MET signalling 
Kidney tissue is an abundant source of hepatocyte growth factor (HGF) a stromal cell-derived 
cytokine involved in cell proliferation, tissue regeneration, tumour growth and tumour 
invasion through the HGF/scatter factor (SF):c-MET pathway (Cantley et al., 1994). HGF 
binding to MET leads to its phosphorylation and subsequent recruitment of adapter proteins 
such as Gab1, Gab2, SHC, STAT3 and PI3K with downstream activation of Ras/MAPK and 
PI3K/AKT pathways (Figure 2) resulting in RCC growth and metastasis (Eder et al., 2009). 
Different studies have shown that HGF and its receptor c-MET are overexpressed in RCC and 
play a significant role in the progression of RCC (Horie et al., 1999; Natali et al., 1996). 
Moreover, VHL-negative RCC cells exhibit cell invasion and branching morphogenesis in 
response to HGF (Koochekpour et al., 1999). c-MET has also been shown to be constitutively 
phosphorylated in RCC and high levels of serum HGF/SF in RCC patients are associated with 
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reduced survival (Tanimoto et al., 2008). Presently, MET is being targeted in clinical trials for 
the treatment of RCC (Giubellino et al., 2009). Strategies involve preventing c-MET 
autophosphorylation; prevention of HGF binding to c-MET and lastly targeting the signalling 
cascade of activated c-MET (Toschi & Janne, 2008). One such investigational drug is AMG 102, 
a fully human mAb that blocks HGF/SF binding to c-EMT and blocks signalling events 
driving tumour proliferation, migration, invasion and survival (Figure 2). Reports of a phase II 
trial with AMG 102 identified that although the drug brought about tumour burden reduction 
and long-term disease stability, it was unclear from the study whether this drug is capable of 
tumour growth inhibition in a histologically diverse population of patients with mRCC 
(Schoffski et al., 2010). Other drugs currently in development include foretinib (GSK1363089) 
an oral multi kinase inhibitor of MET and VEGFRs (Kataoka et al., 2011), ARQ 197, a selective 
non-ATP competitive inhibitor of MET (Adjei et al., 2011) and a range of orally available c-
MET kinase inhibitors namely (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-
yl-1H-pyrazol-4-yl)-pyridin-2-ylamine (PF02341066) and 2-[4-(3-quinolin-6-ylmethyl-3H-
[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol (PF04217903) (Yamazaki et al., 2011). 
The efficacy of these drugs have yet to be investigated in patients with RCC. Thus, further 
investigations of these potentially effective therapeutic drugs is warranted at this time. 
11. Conclusions and future directions 
RCC is similar to other cancer types in that it is asymptomatic initially with a lack of early 
warning signs. This results in a high percentage of patients presenting with metastasis at 
diagnosis or indeed relapse following nephrectomy. RCC is also known for its unpredictable 
clinical behaviour. Historically RCC and mRCC has been associated with treatment 
resistance and poor prognosis. However, with ever increasing knowledge of angiogenesis 
and aberrant signalling pathways in patients with RCC recent basic and clinical 
developments has exerted a substantial impact on outcomes for patients with mRCC.  
Throughout the past fifteen years there has been an increased understanding of the tumour 
biology of RCC. There is now a myriad of treatment options available making the treatment 
of RCC and mRCC immensely complex. Sequential therapy with targeted agents is currently 
the standard of care while combination therapies are still under active investigation. 
Combination therapies can provide additive or synergistic effects resulting from more 
complete blockade of the many aberrant signalling cascades outlined above. This approach 
can also prevent or delay the development of resistance that would eventually arise with 
single-agent therapy owing to signalling pathway redundancy. Despite recent 
advancements, however, current chemotherapeutics can only increase the overall survival of 
patients from weeks to months and unfortunately cannot cure RCC. Combination regimes 
have many drawbacks and in many instances have not proven beneficial in terms of inferior 
efficacy and excessive toxicity. It is also clear from the multitude of described and ongoing 
clinical trials that patient response to targeted agents is not universal. Thus, we have 
reached the stage where there is compelling need to identify new combinations with the 
goal of providing maximal efficacy with manageable toxicity. Increased knowledge of 
mechanisms of disease, drug resistance, new targets and new targeted agents may 
eventually provide optimal strategies for patients with RCC and mRCC. 
Another area of note to improve the treatment of patients with RCC and mRCC is the 
identification of genetic and epigenetic markers as promising biomarkers (Pal et al., 2010; 
Vickers & Heng 2010) . This may indicate the suitability of a patient to treatment with one 
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agent above another and also the optimal sequential or combination of therapies. Many RCC 
biomarkers have been examined over the past decade and include VHL gene mutation, 
plasma VEGF, tissue and plasma VEGFRs, tissue HIF and tissue and serum CAIX as 
outlined already in this report. Others include B7-H1 a cell surface glycoprotein that acts as 
a negative regulator of anti-tumoural T cell-mediated immunity and whose high levels of 
expression in patients with RCC has been associated with shorter survival (Vickers & Heng, 
2010).   Another prognostic biomarker includes neutrophil gelatinase-associated lipocalin 
(NGAL). NGAL is elevated in a number of cancers and has been linked to MMP-9, which is 
involved in the degradation of the extracellular matrix and therefore invasion and 
metastasis. Thus, lower levels of NGAL is associated with longer PFS in RCC patients 
(Vickers & Heng, 2010). Despite growing research in this area, however, there are currently 
no biomarkers used in the clinical management of patients with RCC.  Future studies such 
as the NIH funded Cancer Genome Atlas project may provide further insight into the 
genome, mRNA and micro RNA transcriptome and methylome of RCC revealing the 
pathways and networking that is aberrant in RCC and thus aid in the identification of new 
biomarkers and therapeutic agents. Furthermore, the use of increasingly sophisticated 
integrative multivariate models which incorporate both molecular and genetic information 
will ultimately aid in the development of curative, non-toxic personalised therapies. Thus, 
research is ongoing and newer improved technologies hold promise in the expansion of our 
knowledge of pathogenesis and determinants of outcome. In summary, in the future 
researchers and clinicians alike will have to unite and develop a workable cohesive strategy 
to optimise use of available agents as well as those undergoing clinical trials and identify 
optimal strategies for the successful treatment of patients with RCC. 
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